World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
108
Citations
47850
World Ranking
969
National Ranking
41

Medicine

D-Index
109
Citations
52038
World Ranking
5709
National Ranking
316

Nadia Harbeck publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nadia Harbeck sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,102 publications — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nadia Harbeck D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nadia Harbeck sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 109 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Nadia Harbeck is affiliated with Ludwig-Maximilians-Universität München in Germany. Their research spans primarily the field of Medicine with notable contributions to Biochemistry, Genetics, and Molecular Biology. Within these domains, the subfields of Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Radiology, Nuclear Medicine, and Imaging have been prominent areas of study.

Their main topics of research focus on Breast Cancer Treatment Studies and Advanced Breast Cancer Therapies. Additional areas include HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, and Breast Lesions and Carcinomas.

Frequent co-authors collaborating with Nadia Harbeck include:

  • Rachel Wuerstlein
  • Oleg Gluz
  • Peter A. Fasching
  • Diana Lüftner
  • Rachel Würstlein

Their work has been published extensively in several key venues, including:

  • Annals of Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • Geburtshilfe und Frauenheilkunde
  • Breast Care

Notable papers with publication year and venue include:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer, 2022, New England Journal of Medicine
  • Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial, 2020, The Lancet
  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer, 2021, Annals of Oncology

Best Publications

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

    Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi

  • Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Debu Tripathy;Seock Ah Im;Marco Colleoni;Fabio Franke

  • Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Seock-Ah Im;Yen-Shen Lu;Aditya Bardia;Nadia Harbeck

  • Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

    Elizabeth A Mittendorf;Hong Zhang;Carlos H Barrios;Shigehira Saji

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    A. Gennari;F. André;C.H. Barrios;J. Cortés

  • Triple-negative breast cancer—current status and future directions

    O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

    Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck

  • Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

    Michael Untch;Peter A. Fasching;Gottfried E. Konecny;Stephan Hasmüller

  • Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

    F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck

  • Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy

    M Schmitt;N Harbeck;C Thomssen;O Wilhelm

  • Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).

    M.J. Duffy;N. Harbeck;M. Nap;R. Molina

  • Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.

    Hans-Joachim Stemmler;Manfred Schmitt;Amina Willems;Helga Bernhard

  • Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

    Fritz Jänicke;Manfred Schmitt;Lothar Pache;Kurt Ulm

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

Frequent Co-Authors

Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Christoph Thomssen
Christoph Thomssen University of Göttingen
Manfred Schmitt
Manfred Schmitt Technical University of Munich
Hans Kreipe
Hans Kreipe Hannover Medical School
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Sibylle Loibl
Sibylle Loibl Goethe University Frankfurt
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Jens Huober
Jens Huober Kantonsspital St. Gallen
Hope S. Rugo
Hope S. Rugo University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine isn’t limited to becoming a physician. The healthcare field offers a variety of rewarding paths, many of which are accessible through flexible online education. For those considering advanced nursing roles, cheap online dnp programs can make it more affordable to earn a Doctor of Nursing Practice. Pharmacists in training can pursue their goals through online pharmacist programs, offering both convenience and recognized qualifications.

Beyond clinical roles, the healthcare industry also needs professionals to manage patient records and navigate insurance claims. Accredited rhit programs online prepare students for certification in health information management—a field that’s growing with the demand for digital records. Additionally, medical coding certification can open doors to in-demand administrative roles, often with the flexibility to work remotely.

These pathways offer alternative or complementary careers to medical school, each with unique benefits and educational requirements. Exploring these options can help you find a niche in healthcare that fits your interests, budget, and lifestyle.

Best Scientists Citing Nadia Harbeck

Trending Scientists

Recently Published Articles